1. Scrip
  2. >>Focus On Asia

GNT Eyes Unmet Need As Novel Ischemic Stroke Therapy Moves To Phase III

Breaks New Ground For Korean Pharma

 
• By Jung Won Shin

Korea's GNT Pharma is set to take its first-in-class, multi-targeted stroke therapy Nelonemdaz into Phase III, raising hopes for a new treatment that could sharply reduce disabilities and death in stroke patients. 

brain scan
GNT Aims To Launch Nelonemdaz In Korea By 2025 • Source: Alamy

Bioventure GNT Pharma Co., Ltd has received approval from South Korea's Ministry of Food and Drug Safety to begin a Phase III study with its first-in-class, multi-targeted stroke therapy nelonemdaz, formerly known as Neu 2000.

It is the first such clearance for a Korea-developed stroke therapy and only the second time globally for a neuroprotective drug for stroke patients receiving endovascular thrombectomy to enter Phase III development, following Canadian firm NoNO Inc.’s NA-1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

 
• By Jung Won Shin

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

More from Focus On Asia